Podcasts about medicines

Multiple protests have been taking place in Delhi over the past week. Hundreds of women have come together in India's capital to protest against a series of sexual assaults - most recently the alleged gang-rape of a 17-year-old near Delhi university's campus. Anita speaks to the BBC's South Asia correspondent Azadeh Moshiri.The manufacturers of a new weight loss drug are warning women to beware of dangerous fakes being offered. The new medication is called Retatrutide. Although you can find it for sale on websites, it's not approved and is still in clinical trials. Dr Emily Pegg the UK medical director of the drug company Eli Lilley, the makers of Retatrutide and Dr Alison Cave, the chief safety officer of the Medicines and Healthcare Regulatory Authority join Anita Rani to discuss the issues.A photography exhibition starts at the Vagina Museum in London next week called Just Because We Smile, Doesn't Mean We're Over It. The images are of more than 100 people who have experienced miscarriage, baby loss or infertility. It is the passion project of Bex Gunn, who along with Laura Buckingham runs The Worst Girl Gang Ever Foundation. Bex and Laura join Anita to explain why they founded their charity and the community that are reflected in these photos.The fourth part of our listener series 'When My Body Surprised Me'. Saba describes the impact weight training for the first time in her 60s has had on her life. Helen Rebanks believes the unsung heroes of rural life are often the wives whose behind-the-scenes efforts keep both the family and the business afloat. Descended from generations of Cumbrian farmers, she still lives in the Lake District. Her bestselling 2023 book, The Farmer's Wife, has inspired a play by the same name, running at the Theatre By The Lake in Keswick until 10 October. Helen joins Anita along with playwright Hannah Khalil to discuss the often-overlooked role of farmers wives. Presented by: Anita Rani. Producer: Louise Corley

Health is one of those areas you can churn through cash. It's expensive to visit your GP, but also expensive to fund. The amount taxpayers spend on health has one up 100% over the past decade. It was around 15 billion in 20216. It's now up over 30. The population has not increased by that much. Only roughly 15%. But there are always better medicines to buy. Unions to settle pay negotiations with. New equipment to buy. Hospitals to replace. It's a money pit. Every election we get the same message, which is basically, let's put more money in the pit. And both Labour and National are saying they will do this. Hell, even ACT is saying the same. But are we missing a trick by always focussing on money in and patients out? Diabetes and obesity are massive problems for the health system. As is aging, though we can't do much about that. But where is the focus in this campaign, outside of New Zealand First's policy, on the food pyramid and keeping ourselves healthy and fit? You are what eat. That's not just an old saying. It's science. To his credit, Robert F. Kennedy Jr. is pushing this in the States. Why aren't we? If we want to keep the status quo and continue funding an ambulance at the bottom off the cliff then we're going the right way about it.See omnystudio.com/listener for privacy information.

The DTB podcast returns with a new format, and a new host: Dr. Hannah Harris, urgent care GP and now Clinical Editor of DTB.   In this episode, Hannah is joined by Professor Barbara Mintzes and Carol Devine, a patient and second-generation victim of Diethylstilbestrol (DES), to examine the long-term, multigenerational impacts of this synthetic oestrogen prescribed in pregnancy to prevent miscarriage from the 1940s to 1980s. They discuss why DES continued to be prescribed despite early proof of inefficacy and harm, Carol's personal health struggle as a "DES Daughter," and the ongoing fight for government recognition and patient care.     This episode also highlights key clinical updates from the September issue of the Drug and Therapeutics Bulletin, including a commentary by the new Editor-in-Chief, Dr. Gordon Mallarkey, on precision medicine in COPD, non-hormonal treatments for polyendocrine metabolic ovarian syndrome, diagnosis of spasticity, and continuous glucose monitoring in type 2 diabetes.   Read the issue on our website: https://dtb.bmj.com/content/64/9.   We would love to hear from you with comments or questions via email (dtb@bmj.com), or you can find us on X with the handle @DTB_BMJ, and also LinkedIn and Facebook under “Pharmacy at BMJ Group”.   The DTB Podcast is hosted by Hannah Harris. It is produced by Hannah Harris and Letícia Amorim. It is edited by Letícia Amorim.

Welcome to PGX #217PGX: Raw & Real is simple. I sit with people who've lived through something and/or made it big.This isn't meant to be inspiration or a template for life (for that, you can check out PGX Ideas).This space is different. It's their story, as they experienced it.In this episode, I spoke to Madhukar Gangadi Reddy — Founder & CEO of MedPlus Health Services.Timestamps:00:00 - Trailer03:13 - Why Fake Medicines Are Everywhere06:46 - Can Your Chemist Tell?09:58 - Is A Fake Pill Just Sugar?14:35 - Inside India's Fake Medicine Factories17:05 - From Wharton To 47 Stores19:41 - Why Patients Chase Cheap Medicines23:00 - Is 80% Off Too Good?24:26 - Do Doctors Get Kickbacks?29:02 - The Secret Doctor-Chemist Deal31:43 - Why Medicines Could Cost Half33:16 - How To Spot Fake Medicines42:56 - Fake Paneer Reveals A Bigger Problem51:07 - Can You Really Trust MedPlus?1:01:15 - Is MedPlus Inflating Medicine Prices?1:04:24 - How Insurance Changed HealthcareEnjoy.— Prakhar

In this episode, we're talking about generic medicines. We're going to outline what they are, how they end up on the market and perhaps in your medicine cabinet and the advantages/ disadvantages of them.  Remember, you can get in touch with us via clinical.research.intro@gmail.com. Please feel free to send questions, comments and compliments for Elyse to read out on the pod. It's fun to make Debbie squirm! Credit to our friend Sam Winnie for their awesome and cute music. Check out their work at https://www.samwinnie.com/ References -   https://www.thebureauinvestigates.com/stories/2025-06-25/what-are-generic-drugs-and-are-they-safe https://www.ummhealth.org/simply-well/the-pros-and-cons-of-using-generic-drugs https://www.moneysavingexpert.com/news/2016/06/revealed-huge-price-differences-between-branded-and-own-brand-medicines-and-generic-equivalents/

In this episode, Dr Heather Kennedy is joined by Dr Ailie Young, Consultant in Acute Medicine with special skill in Obstetric Medicine. They discuss breathlessness in pregnancy, covering the approach to initial assessment and investigations in the AMU, the management of acute exacerbation of asthma in pregnancy, and the investigation/management of PE in pregnancy. Dr Ailie Young is a Consultant in Acute and General medicine with a specialist skill in Obstetric Medicine. She is particularly interested in the investigation and management of the acutely unwell pregnant patient that is admitted to the Acute Admissions unit with a medical problem. Dr Heather Kennedy is an ST4 in Acute Internal Medicine in Southeast Scotland and a member of the Trainees and Members' Committee. -- Useful Links -- UK Teratology Information Service - https://uktis.org Best Use of Medicines in Pregnancy (BUMPS) - https://www.medicinesinpregnancy.org The Maternal Care Bundle (See Element 1 VTE) - https://www.england.nhs.uk/long-read/the-maternal-care-bundle/#element-1-venous-thromboembolism-vte Green-top guideline Thrombosis and Embolism during Pregnancy and the Puerperium - https://www.rcog.org.uk/guidance/browse-all-guidance/green-top-guidelines/thrombosis-and-embolism-during-pregnancy-and-the-puerperium-acute-management-green-top-guideline-no-37b/ Recording Date: 16 July 2026 -- Follow us -- https://www.instagram.com/rcpedintrainees -- Upcoming RCPE events -- https://www.rcpe.ac.uk/events -- Become an RCPE Member -- https://www.rcpe.ac.uk/membership/join-college Feedback: cme@rcpe.ac.uk This podcast is from the Trainees & Members' Committee (T&MC) of the Royal College of Physicians of Edinburgh (RCPE).

A chance lunchtime conversation changed Dr Caroline Copeland's career. Newly arrived at St George's as a pharmacologist, she discovered an old file. Two decades of coroners' reports were sitting in paper files. Caroline saw what could be learned from them and changed direction to help keep the programme alive.  The rest, as they say, is history.Today Caroline is Senior Lecturer in Pharmacology and Toxicology at King's College London and Director of the National Programme on Substance Use Mortality. We talk about the people behind the statistics, the role of coroners and toxicology, deprivation and stigma, and why the details recorded after a death matter for preventing the next one. The conversation takes us from naloxone delivered by drone to the changing illicit drug supply and the difficulty of detecting Nitazenes after death.Our micro discussion continues the theme and explores Caroline's research suggesting that opioid-related deaths in England and Wales have been substantially underestimated. Why does this matter and what can we do about it? https://www.sciencedirect.com/science/article/pii/S0955395925002725?via%3DihubAs ever, Caroline shares a memory-evoking medicine, a career anthem and a book. As ever, it is the stories behind the choices that we love. In the Final Ingredient, Gimmo tells the story of Bixonimania: a fictional illness that found its way into confident AI answers. A reminder to check the source, however convincing the wording.Mentioned in this episodeCaroline Copeland at King's College LondonNational Programme on Substance Use MortalityResearch on naloxone delivery by droneNature: Scientists invented a fake disease. AI told people it was realhttps://www.bbc.co.uk/sounds/play/m002grqm Can we reverse rising drug deaths? BBC Inside Health https://www.bbc.co.uk/sounds/play/m0021qsl The Drug Death Detectives BBC Radio 4 Follow The Aural Apothecary on LinkedIn and find more episodes at theauralapothecary.com. We are on Instagram @auralapothecary. From Prescription to Ocean — A TEDx Talk by Jamie HayesWe're incredibly proud to share that Aural Apothecary co-host Jamie Hayes has taken to the TEDx stage with a thought-provoking talk:  Prescription to Ocean: The Hidden Impact of Medicines https://www.youtube.com/watch?v=swCLNaAG5qYJamie explores a fascinating and urgent question: What happens to our medicines once they leave the prescription pad — and how do they impact the world beyond the patient? It's a journey that connects healthcare, the environment, and our shared responsibility for the future. You'll never think about prescribing (or taking) medicines in quite the same way again. Please take a few minutes to watch, reflect, and share — this is a conversation worth having.

Welcome to the Oncology Brothers podcast! In this episode, we dove deep into the groundbreaking advancements in pancreatic cancer treatment, focusing on the recent approval of daraxonrasib.   Join us as we welcome Mark Goldsmith, MD, PhD, CEO of Revolution Medicines, who shared his inspiring journey from clinical practice to the biotech industry. Discover the challenges and triumphs behind bringing this first-in-class drug to market, and learn about the significant impact it has on patient outcomes.   Keypoints: Daraxonrasib is a first-in-class RAS inhibitor approved for the treatment of pancreatic cancer, targeting a mutation present in over 90% of cases. The drug's development represents a major shift in pancreatic cancer, moving from a historically untreatable disease to a promising target for precision medicine. Early clinical trial results demonstrated remarkable tumor shrinkage, driving urgency to bring the therapy to patients. Management of side effects, including rash and gastrointestinal issues, is essential for optimal patient outcomes. Ensuring patient access—despite high treatment costs—remains a priority, with patient assistance programs and insurance navigation support in place. Future directions include combination therapies and the goal of transforming pancreatic cancer into a manageable chronic disease.   We discussed the critical gaps between academic research and community practice, the importance of understanding side effects, and the financial implications of new therapies. Dr. Goldsmith also highlighted the future of pancreatic cancer treatment and the ongoing commitment to improving patient care.   Whether you're a healthcare professional, a patient, or simply interested in the latest in oncology, this episode is packed with valuable insights and information.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o  Follow us on social media: ⁠X/Twitter: https://x.com/oncbrothers  Instagram: https://www.instagram.com/oncbrothers  Website: https://oncbrothers.com/    Don't forget to like, subscribe, and hit the notification bell for more episodes on the latest in cancer treatment and research! #PancreaticCancer, #Daraxonrasib, #RASinhibitor, #DrugDevelopment, #OncologyBrothers

Send us Fan MailWhat if one of the biggest assumptions in modern drug development is wrong?For decades, we've tried to find the one molecule responsible for a medicine's effects, purify it, manufacture it and throw away everything else.But what if, in some cases, the complexity is actually the medicine?Today we're exploring a very different approach to drug development - one that takes complex botanical mixtures and tries to turn them into reproducible, FDA-approved pharmaceuticals.Joel Stanley is CEO of AJNA BioSciences ( https://ajnabiosciences.com/ ) and one of the people who helped launch the modern CBD movement.Joel is one of the Stanley brothers behind Charlotte's Web ( https://www.charlottesweb.com/ ), the company that helped bring CBD into the mainstream after the remarkable story of Charlotte Figi and the use of cannabis-derived preparations in severe epilepsy.But Joel's journey has now moved into a very different phase.At AJNA BioSciences, he is pursuing something that sits at the intersection of natural medicine and highly regulated pharmaceutical development: FDA-approved botanical drugs.And that distinction is important.Rather than necessarily isolating a single active molecule, AJNA is developing standardized, full-spectrum botanical formulations - using modern chemistry, manufacturing and controls, clinical trials and FDA regulatory science to try to turn complex plant and fungal preparations into reproducible pharmaceutical products.The company currently has programs spanning cannabinoids and tryptamines, with targets including autism-spectrum disorder, generalized anxiety disorder and PTSD. Its pipeline includes a cannabinoid formulation that has completed Phase 1 and is moving toward Phase 2, as well as a full-spectrum psilocybin/tryptamine program.And here's the really interesting part:The FDA actually has a specific regulatory framework for botanical drugs ( https://www.fda.gov/about-fda/cder-offices-and-divisions/what-botanical-drug ). The agency acknowledges that these products can contain complex mixtures in which the precise active constituents - and even all of their biological activities - may not be completely known. Instead, developers can establish consistency through a combination of raw-material controls, analytical chemistry, manufacturing controls, biological assays and clinical evidence.There are currently only four botanical products approved as prescription drugs in the United States, according to the FDA.So Joel is attempting to navigate a relatively uncommon - and potentially very powerful - pathway toward something that could fundamentally change how we think about plant-based medicines.#JoelStanley #AJNABioSciences #BotanicalMedicine #BotanicalDrugs #Psychedelics #PsychedelicMedicine #Psilocybin #CBD #Cannabis #Cannabinoids #DrugDevelopment #Pharmaceuticals #FDA #MentalHealth #Neurology #Autism #Anxiety #PTSD #Biotechnology #Biotech #DrugDiscovery #PlantMedicine #NaturalMedicine #FutureOfMedicine #ProgressPotentialAndPossibilitiesSupport the show

Genetic medicine has already begun to transform the treatment of some inherited diseases, but the brain remains one of its most formidable frontiers. For disorders such as Huntington's disease and ALS, scientists may understand key genetic contributors and have increasingly powerful editing tools, yet getting those tools safely, efficiently, and selectively into vulnerable neurons is another matter entirely. Evox Therapeutics is developing an approach built around naturally occurring nanoparticles that cells use to communicate, known as exosomes, as delivery vehicles for CRISPR-based medicines. We spoke with Per Lundin, the company's co-founder and CEO, about the promise and limitations of exosome-enabled gene editing, how the company is prioritizing its pipeline, and what it will take to establish this emerging therapeutic strategy in the clinic.

In this episode, Fiona chats with Donal Murphy, Deputy CEO and Head of International and Regulatory Affairs at the National Office of Animal Health (NOAH). NOAH is the trade organisation representing the UK animal health industry, and in this conversation, Donal shares a detailed look at how veterinary medicines are developed, regulated, monitored, and supplied. Donal, who spent his early career working in veterinary practice, provides details on the scale and structure of the UK and European animal health sectors, the responsibilities of regulators and manufacturers, the importance of pharmacovigilance, environmental considerations around parasiticides, and the challenges involved in maintaining reliable medicine and vaccine supply chains. Key take outs:Veterinary medicines are highly regulated: products must meet strict standards for safety, quality, and efficacy before they are authorised, with extensive data submitted to regulators such as the Veterinary Medicines Directorate (VMD). Reporting suspected adverse events matters: Pharmacovigilance relies on vets, farmers, and animal owners reporting concerns, including suspected lack of efficacy, side effects, human exposure, or residue issues, so regulators can identify trends and act when needed. Medicine supply chains are complex: Global manufacturing, batch testing, rising vaccine demand, Brexit, and emerging diseases all influence availability, making forward planning and ordering crucial for practices and farms. A must-listen for vets, farmers and animal owners if you want to know more about medicines in the UK!If you enjoyed this episode, please share with your friends, colleagues and network. It really helps us reach a wider audience - thank you!Notes:If you use, prescribe, or advise on veterinary medicines, please take the time to report any suspected adverse events or suspected lack of efficacy through the appropriate reporting routes. Your reports help strengthen product safety, improve guidance, and support the responsible use of medicines across the animal health sector. National Office of Animal Health (NOAH) https://www.noah.co.uk/Veterinary Medicines Directorate (VMD) https://www.gov.uk/government/organisations/veterinary-medicines-directorateEuropean Medicines Agency (EMA) https://www.ema.europa.eu/en/about-us/who-we-are/veterinary-medicines

越来越机警的消费者肯定能感受到，很多时候消费的欲望不是自然形成的，而是被品牌精心诱导出来的——尤其是在你不熟悉的领域。但一旦对某些产品、品类形成了明确的印象，已经植入大脑的概念又很难被轻易更改——诺兰在他16年前上映的电影《盗梦空间》里已经指出了这一点。这么说的话，很多消费观念和大众认知，其实都值得被重新审视。本期节目我们尝试从一个国内流传度颇高的说法，也就是所谓的“澳洲保健品好/澳洲以保健品出名”入手，来尝试倒推整个概念是如何在澳洲和中国两地不断形成、流转和变化的。注：本期节目的内容基本不涉及讨论“保健品”中的功能成分及具体功效，因为这不是我们的关注重点。建议将其视作一个单纯的商学院战略或营销案例，来思考功效之外的一些东西。| 主播 |肖文杰、约小亚| 时间轴 |00:33 考考你对大洋洲的熟悉程度（误03:51 澳洲的“非传统医疗”反而很有传统09:55 “一天一粒维生素”的美式神话14:35 澳洲的保健品和药品接受同样的监管吗？19:16 生产和监管流程都不监督保健品的功效21:33 Swisse通过高强度营销打开市场31:24 从海外代购到跨境海淘的自由贸易窗口36:23 如何做一次有效的观念植入？| 延伸资料 |Medicine in colonial Australia, 1788-1900 | MJAFirst Blackmores health food store - Australian food history timelineReview of Medicines and Medical Devices Regulation – Stage TwoUnderstanding listed and registered complementary medicine regulationRadek Sali: How Swisse Built a $2 Billion Wellness Empire汤臣倍健2026年半年度报告跨境爆品反思：“洋品牌”的兴奋与忧患跨境电商保健品：保税仓模式绕开蓝帽子审批的深度分析Reuters-Hong Kong's Biostime to buy Australian vitamin maker Swisse for about $1 billion| 后期制作 |潘鑫| 声音设计 |刘三菜| 收听方式 |你可以通过小宇宙、苹果播客、Spotify、喜马拉雅、网易云音乐、QQ音乐、荔枝、豆瓣等平台收听节目。| 认识我们 |微信公众号：第一财经YiMagazine联系我们：thatisbiz@yicai.com

In this new Let's Talk Cancer episode, Dr Aparna Parikh, Gastrointestinal oncologist and Program Director for GI Medical Oncology at Mass General Brigham, discusses access to cancer care and what it will take to make equitable care a reality for patients everywhere. Hosted on Acast. See acast.com/privacy for more information.

*This episode of the pharmaphorum podcast is brought to you in association with Klick Health* Europe continues to offer major life sciences advantages: deep scientific talent, strong clinical expertise, mature research infrastructure, and significant manufacturing capability. Indeed, biotech companies continue to invest in Europe as a long-term hub for scientific innovation, clinical research, and economic growth. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Giancarlo Benelli, SVP & Head of Europe at BeOne Medicines, for a conversation on what Europe must do, however, in order to remain globally competitive. Benelli discusses EFPIA's latest reports on Europe's competitiveness as a location for the life sciences industry, as well as exploring why it is at the same time losing ground to the US and to China. Additionally, Benelli comments on the importance of regulatory stability looking forward. You can listen to episode 275 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it – and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from. *This episode of the pharmaphorum podcast is brought to you in association with Klick Health*

Welcome all to IS PHARMACOLOGY DIFFICULT Podcast! I am Dr Radhika VijayIt is the New Bonus Episode! -"What Medicines Should You Put in First Aid Box?" The Podcast is for all- doctor, pharmacologist, med student, pharmacist and laymen interested in science of Pharmacology, drugs and medicinesMy podcast is featured in "TOP 20 PHARMACOLOGY PODCASTS"- Check the link here:https://podcast.feedspot.com/pharmacology_podcasts/My podcast is featured in " 40 BEST INDIA EDUCATION PODCASTS"- Check the link here:https://podcast.feedspot.com/india_education_podcasts/My podcast is featured in "BEST SCIENCE PODCASTS"- Check the link here:https://podcasts.feedspot.com/india_science_podcasts/My podcast is featured in "BEST INDIAN MEDICAL PODCASTS". Check the link here:https://podcasts.feedspot.com/india_medical_podcasts/?feedid=5503395For all the updates and latest episodes of my podcast, please visit www.ispharmacologydifficult.com where you can also sign up for a free monthly newsletter of mine."Pharmacology Further" E-Newsletter and Podcast:The links for these are at all my websites and specifically:Link for E-Newsletter: https://pharmacologyfurther.substack.com/Link for the E-Newsletter Podcast: https://www.pharmacologyfurther.comIt actually contains lot of updates about the medical sciences, drug information and my podcast updates also.You can follow me on different social media handles like twitter, insta, facebook and linkedin. They all are with same name "IS PHARMACOLOGY DIFFICULT". If you are listening for the first time, do follow me here, whatever platform you are consuming this episode, stay tuned, do rate and review on ITunes, Apple podcasts, stay safe, stay happy, stay enlightened, Thank you!!Please leave Review on Apple podcasts!My E-Newsletter sign up at Substack!Connect on Twitter & Instagram!My books on Amazon & Goodreads!

I started dancing 5 Rhythms about a year ago, and it changed my life. I met a whole new tribe of like minded people who have become fast friends, learned to inhabit my body in ways I never had before, healed some of my childhood wounding, discovered Joy in a way that had always eluded me, and enjoyed a year of personal freedom, exploration and growth which have profoundly changed me. Who knew that dance could be so powerful?   Dr. Geeta Maker-Clark, herself a physician and dancer, understands the power of dance, and the science behind its healing benefits. But she also understands the power of other cultural and lifestyle traditions which form part of the ancient medicine practiced by our ancestors. In this episode of the MindHealth360 Show, Dr. Geeta Maker-Clark raises an important question: have we become so focused on increasingly sophisticated treatments, testing and biomarkers that we are overlooking some of the most fundamental determinants of our mental and physical health? Drawing on her new book Medicine for All People: Science and Ancient Wisdom for Revolutionary Healing, Dr. Maker-Clark explores the medicines we may have forgotten to value: nature, food, plants, relationships, community, movement, dance, gratitude and play. Dr. Maker-Clark's approach brings together biomedical science, integrative medicine and ancestral wisdom without dismissing any of them. She argues that even functional medicine can become reductionist when it focuses exclusively on biomarkers and biochemical precision, while overlooking the environments and relationships in which people actually live.  We explore why health is not simply created in the exam room;  how loneliness and social connection can affect stress physiology, inflammation, immunity and mortality risk; why our increasingly indoor and digital lives may be distancing us from important biological inputs; and why Getta describes community as 'the vagal nerve stimulator of our times'. We also look at the emerging science behind some of these forgotten medicines. Why might time in nature affect mood and circadian biology? What happens when dance brings together aerobic movement, rhythm, memory, emotion and social connection? And can practices such as gratitude help us train our attention without denying the reality of suffering? Finally, we explore "primordial prevention": the idea that rather than waiting for disease or even its risk factors to emerge, we can create environments and ways of living in which those risks are less likely to develop in the first place. In this episode, you will learn: Why medicine belongs to everyone and should not be reserved for those who can afford expensive testing, supplements or specialist care. Why modern medicine may be overlooking the health effects of nature, food, community, movement, relationships, gratitude and play. How our increasing disconnection from nature may be affecting mental and physical health, particularly for children growing up in increasingly indoor and digitalised environments. Why social connection is biological as well as emotional, influencing stress physiology, inflammation, immunity, sleep and mortality risk. Why dance brings together movement, music, memory, emotion, culture and human connection in ways that may have particular relevance for mental health.  Why gratitude is a practice of attention rather than denial and what research suggests about its relationship with mental health and resilience. Why rebuilding trust, including trust in ourselves, can be a powerful part of healing. What primordial prevention means and why addressing the conditions that give rise to disease could fundamentally change the model of care. Take the conversation further at IMMH 2026 At the Integrative Medicine for Mental Health (IMMH) Conference 2026, Dr. Geeta Maker-Clark will take one of the central ideas from this conversation, and one close to my heart, into greater clinical depth in her session: Could dance have a serious role to play in mental healthcare? In her CE/CME presentation Medicine for All People: Dance, Neuroscience, and Embodied Mental Health she will explore how dance brings together aerobic movement, bilateral motor engagement, music, memory, emotional expression and interpersonal synchrony and examine the emerging evidence for its effects on neuroplasticity, stress regulation, mood, cognition and social connection. She will also consider dance through the lens of ancestral and cross-cultural healing traditions. Long before movement was studied through neuroscience and psychophysiology, humans danced collectively. What might modern mental healthcare learn from a practice that has brought together body, emotion, rhythm and community across cultures for millennia? Join Dr. Maker-Clark and more than 50 leading clinicians and researchers at IMMH 2026, October 8–11 in San Diego or online,to explore the emerging science behind whole-person approaches to mental health and their potential application in clinical practice. Get tickets now: https://www.immh.org/immh-2026/

Digital Health Unplugged returns as host Jordan Sollof is joined by Lawrence Tallon, chief executive at the Medicines and Healthcare products Regulatory Agency (MHRA), to discuss the newly published blueprint for regulating AI in healthcare. The National Commission into the Regulation of AI in Healthcare published its recommendations today (10 September), setting out how the UK can give patients faster, safer access to AI in their care. Tallon discusses some of the key recommendations and what they could mean for patients, clinicians and developers of AI-enabled medical devices. Among the proposals is a staged, “L-plates” style approach to authorising new AI models, designed to enable promising technologies to reach patients more quickly while evidence about their safety and effectiveness continues to develop. Sollof asks Tallon how the proposed system would work and, crucially, how regulators could ensure that speeding up access does not expose patients to greater risk. The discussion also explores the commission's call for continuous, real-world monitoring of AI-enabled medical devices throughout their working lives, including who would be responsible for monitoring systems once they are deployed and why a single point of approval may no longer be sufficient for AI technologies that can change over time. Tallon is questioned on proposals to make safety information about individual AI-enabled medical devices easier to access, whether patients should be told every time AI is involved in their care and what happens if someone does not want an AI system to be used. The episode also tackles one of the biggest questions surrounding the growing use of healthcare AI: who is accountable when something goes wrong? Sollof then asks what stronger powers proposed for the MHRA could allow the regulator to do when an AI system falls short of expected standards, and whether the commission's recommendations could address concerns about AI scribes and ambient voice technology after reports of errors appearing in patients' medical records. Guest: Lawrence Tallon, chief executive, the MHRA  

Der Markt für Krebsmedikamente ist in Bewegung: Was bedeutet das für Anleger? Michel Doepke, Biotech-Experte bei DER AKTIONÄR, ordnet die Entwicklungen in dieser Episode ein. Hinweis auf Interessenkonflikte: Der Vorstand und Mehrheitsinhaber der Herausgeberin Börsenmedien AG, Herr Bernd Förtsch, ist unmittelbar und mittelbar Positionen über die in der Publikation angesprochenen nachfolgenden Finanzinstrumente oder hierauf bezogene Derivate eingegangen, die von der durch die Publikation etwaig resultierenden Kursentwicklung profitieren können: Moderna, BioNTech, Merck & Co. Pfizer, Gilead Sciences Aktien der Moderna befinden sich in einem Real-Depot der Börsenmedien AG. Hinweis: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlageempfehlungen dar. Die Moderatoren oder der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen.

Spending more money on medicines would pay for itself and strengthen the economy, according to a new report comissioned by Business New Zealand. Currently 5 percent of Aotearoa's health spending goes on pharmaceuticals, compared to an OECD average of just over 13 percent. Business NZ's director of advocacy, Catherine Beard spoke to Lisa Owen.

BusinessNZ's calling for a funding reset on medicines, with a new report highlighting the long-term benefits of investing more into healthcare. The report shows every dollar invested into medicine returns $1.93 to the economy. BusinessNZ CEO Katherine Rich explained that there's long-term benefits into investing more, including boosting productivity and improving the quality of life for New Zealand families. "It takes up to six years to get a new drug through - and these are drugs that are available freely not just in Australia, but around the globe." LISTEN ABOVESee omnystudio.com/listener for privacy information.

BusinessNZ's calling for a funding reset on medicines, with a new report highlighting the long-term benefits of investing more into healthcare. The report shows every dollar invested into medicine returns $1.93 to the economy. BusinessNZ CEO Katherine Rich explained that there's long-term benefits into investing more, including boosting productivity and improving the quality of life for New Zealand families. "It takes up to six years to get a new drug through - and these are drugs that are available freely not just in Australia, but around the globe." LISTEN ABOVESee omnystudio.com/listener for privacy information.

About this episode:   During the recent pandemic, low-income countries struggled to access the COVID-19 vaccine, despite a global framework that had been established for this purpose. In this episode: Tahir Amin, a leader in the access to medicines movement, shares his perspective on what failed during the pandemic and how this experience reflects larger challenges in the availability and affordability of critical medications. Guest:  Tahir Amin, DPLP, is a founder and CEO of the Initiative for Medicines, Access & Knowledge (I-MAK), a nonprofit organization working to address the inequities in how medicines are developed and distributed. Host:  Dr. Josh Sharfstein is distinguished professor of the practice in Health Policy and Management, a pediatrician, and former secretary of Maryland's Health Department.  Show links and related content:  Pharma Monopoly: The Battle for the Future of Medicines—Polity Books (book) Americans' Challenges with Health Care Costs—KFF Patently imperfect—Science Could Patent Reform Lower Drug Prices?—Public Health On Call (March 2023) Transcript information: Looking for episode transcripts? Open our podcast on the Apple Podcasts app (desktop or mobile) or the Spotify mobile app to access an auto-generated transcript of any episode. Closed captioning is also available for every episode on our YouTube channel. Contact us: Have a question about something you heard? Looking for a transcript? Want to suggest a topic or guest? Contact us via email or visit our website. Follow us: @‌PublicHealthPod on Bluesky @‌PublicHealthPod on Instagram @‌JohnsHopkinsSPH on Facebook @‌PublicHealthOnCall on YouTube Here's our RSS feed Note: These podcasts are a conversation between the participants, and do not represent the position of Johns Hopkins University.

What if we expanded our view of medicine as something that's practiced outside of clinics and beyond prescriptions, and began to view it as something that surrounds us every day?   In this episode, Geeta Maker-Clark, MD, makes the case that healing is far bigger than healthcare as we traditionally know it. She talks about the medicines hiding in plain sight — from breath to movement to nourishing meals — and why she prescribes them to all her patients. She explores what it really means to cultivate vitality through small, ordinary, daily practices.   Find the episode highlights, get related resources and view the transcript for this episode at https://experiencelife.lifetime.life/podcast/the-ordinary-medicines-found-in-everyday-life-with-geeta-maker-clark-md   Have thoughts you'd like to share or topic ideas for future episodes? Email us at lttalks@lt.life — we'd love to hear from you!   Follow us on Instagram: @lifetime.life   The information in this podcast is intended to provide broad understanding and knowledge of healthcare topics. This information is for educational purposes only and should not be considered complete and should not be used in place of advice from your physician or healthcare provider. We recommend you consult your physician or healthcare professional before beginning or altering your personal exercise, diet or supplementation program. 

Inceptive CEO Jakob Uszkoreit goes Inside the ICE House to challenge the foundational assumptions of modern drug discovery, arguing that AI will enable medicines that work with the body's natural complexity rather than against it. He discusses Inceptive's partnership with Alnylam Pharmaceuticals and why their RNA interference platform and rich data history make them a uniquely powerful AI collaborator. Uszkoreit explains why partnerships are essential for a small company with broadly applicable technology, and why the long-term prize is therapies that are gentler, earlier, and truly personalized.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we explore groundbreaking advancements, regulatory updates, and strategic partnerships shaping the future of patient care and drug development. Revolution Medicines has achieved a significant milestone with the FDA approval of its RAS inhibitor, daraxonrasib, for metastatic pancreatic cancer treatment. This approval follows an impressive presentation at the American Society of Clinical Oncology meeting that garnered widespread acclaim. Targeting one of the most challenging cancers, this advancement offers renewed hope for patients with limited treatment options and sets a potential new standard in pancreatic cancer therapy. In another promising development, Amgen and AstraZeneca have successfully completed a Phase 3 trial for their drug Tezspire in eosinophilic esophagitis. This success positions Tezspire as a formidable contender in the competitive landscape of inflammatory disease treatments, directly challenging Sanofi and Regeneron's Dupixent. The focus on biologics targeting specific inflammatory pathways underscores ongoing innovation in this area, offering enhanced treatment options for patients. On the regulatory front, the FDA has expanded its authorization for Tivicay, an HIV medication, to include newborns. This move aligns with global efforts to advance pediatric HIV treatment and address public health challenges. Additionally, Roche has secured further FDA approval for diagnostic tests linked to Jazz Pharmaceuticals' oncology drug Ziihera, emphasizing the critical role of companion diagnostics in personalized medicine. Meanwhile, strategic initiatives are also taking shape in pricing agreements. The Trump administration is preparing to announce "most favored nation" pricing agreements with mid-sized biopharma companies as part of ongoing efforts to tackle drug pricing issues. Although these arrangements could lead to lower drug prices, they may also face industry resistance due to potential impacts on revenue. Flagship Pioneering's Profound Therapeutics has partnered with the Gates Foundation in a $35 million effort to discover new drug targets for preeclampsia—a dangerous pregnancy complication. Such collaborations are vital in accelerating research and offering innovative solutions to complex health problems. Artis Biosolutions is expanding its synthetic DNA and mRNA production capabilities with a new facility in Spain. This development highlights the growing importance of genetic medicines and reflects an industry shift towards next-generation therapies like gene editing and RNA-based treatments. On a global scale, CEPI is supporting Minapharm's Ebola vaccine candidate advancement into clinical trials amid a growing outbreak. This initiative is part of a broader strategy to enhance epidemic preparedness through rapid vaccine development and deployment. Another significant move comes from McKesson's $2.25 billion acquisition of Precision Medicine Group. This acquisition aims to strengthen McKesson's oncology and biopharma segments, emphasizing precision medicine's growing role in personalized cancer treatment. In the context of geopolitical dynamics, concerns about Chinese dominance in clinical trials and supply chains have been raised by Congressman Nathaniel Moran. This highlights strategic dependencies and underscores the need for robust domestic capabilities in biopharmaceutical research and manufacturing. In clinical developments, Bausch + Lomb faced setbacks with its phase 2 trial combining dry-eye disease drugs Xiidra and Miebo but remains optimistic as it advances to phase 3 trials. Conversely, Spyre Therapeutics is deprioritizing its anti-TL1A antibody approach following underwhelming phase 2 results for rheumatoid arthritis—a testament to the rigorous validation process required before new therapies can reach patients. Akeso's success with its PD-1xVEGF bispecific antibody ivonescimab in biliary tract cancer demonstrates innovative biologics' potential to expand treatment options beyond traditional indications. In regulatory news concerning Capricor Therapeutics' Duchenne muscular dystrophy therapy, an extended FDA review period reflects careful regulatory evaluation following additional data submissions. These developments paint a picture of a dynamic landscape where scientific innovation is paralleled by regulatory challenges and strategic partnerships aimed at addressing both market demands and pressing health issues. The continued focus on personalized medicine, competitive dynamics in biologics, and global collaboration efforts underscores a transformative period for pharmaceuticals and biotech industries. As these sectors evolve, they hold the promise of delivering more effective treatments worldwide while addressing unmet medical needs across various domains.Support the show

Send us a textNot every consultation about periods or pregnancy comes with a straightforward answer. Join Nik and Lucy as they unpack reproductive health in inflammatory bowel disease, including contraception, medication reviews, pregnancy and breastfeeding, before tackling the questions that often make adolescent menstrual consultations tricky: what is normal, what needs investigating, which treatments can be offered and when to refer. A practical episode packed with useful pointers for the next time you are in your consulting room.Useful LinksThe Best Use of Medicines in Pregnancy website (BUMPS) GP Trainee Essentials support package information, and the Red Whale CalendarSend us your feedback podcast@redwhale.co.uk or send a voice message Sign up to receive Pearls here. Pearls are available for 3 months from publish date. After this, you can get access them plus 100s more articles when you buy a one-day online course from Red Whale OR sign up to Red Whale Unlimited.  Find out more here. Follow us:  Facebook, Instagram, LinkedInDisclaimer: We make every effort to ensure the information in this podcast is accurate and correct at the date of publication, but it is of necessity of a brief and general nature, and this should not replace your own good clinical judgement, or be regarded as a substitute for taking professional advice in appropriate circumstances. In particular, check drug doses, side-effects and interactions with the British National Formulary. Save insofar as any such liability cannot be excluded at law, we do not accept any liability for loss of any type caused by reliance on the information in this podcast.

Revolution Medicines CEO Dr. Mark Goldsmith joins after the company received FDA approval for its pancreatic cancer pill that's priced at roughly $40,000 per month. Then, Goldman Sachs analyst Jim Schneider shares his reaction to Nvidia's latest earnings report that has the stock jumping. Plus, Synopsys CEO Sassine Ghazi joins on the heels of a beat and raise.Squawk on the Street Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Let's dive right into today's top stories, where pioneering advancements and strategic shifts are reshaping how we understand and treat complex diseases. In recent developments, Akeso's PD-1xVEGF bispecific antibody ivonescimab is making waves beyond its initial use in non-small cell lung cancer. The successful completion of a Phase 3 trial for biliary tract cancer marks a pivotal moment, suggesting broader applications of this dual-targeting therapy. Ivonescimab's mechanism—enhancing immune response while inhibiting tumor angiogenesis—could significantly improve patient outcomes across various cancers. However, questions about its efficacy continue to prompt careful scrutiny as it challenges existing treatment paradigms. Regulatory dynamics are equally compelling, with the FDA undergoing potential restructuring under President Trump's nominee for commissioner. The creation of two new deputy commissioner roles is speculated to enhance oversight and accelerate drug approval processes. Such changes are crucial as the FDA navigates increasing demands for rapid evaluations amidst complex pharmaceutical landscapes. Meanwhile, Teva Pharmaceutical Industries finds itself under a competition probe in Turkey, highlighting global antitrust challenges within the industry. As Teva juggles its dual role as a generics leader and an innovator, this scrutiny underscores the delicate balance of maintaining market dominance while adhering to fair competition laws. On the safety front, Baxter International has initiated recalls of two medical products due to particulate contamination concerns. This action underscores the critical importance of rigorous quality control in safeguarding patient trust and safety. Similarly, Vitruvias Therapeutics has recalled thyroid tablets labeled "superpotent," emphasizing precision's vital role in pharmaceutical manufacturing. Eli Lilly is expanding its focus on obesity treatment through Medicare access campaigns for GLP-1 receptor agonists. By targeting older adults, Lilly aims to address obesity as a chronic condition requiring sustained intervention, potentially enhancing health outcomes for millions. Public health remains a pressing concern as Pennsylvania reports its first measles-associated deaths in decades amid rising nationwide cases. This situation highlights the ongoing need for robust vaccination campaigns and public health strategies to combat vaccine-preventable diseases effectively. Cybersecurity is also at the forefront, with Boston Scientific experiencing disruptions from a cyberattack. This incident reflects a broader trend affecting medtech firms globally, underscoring the necessity for robust cybersecurity measures to protect sensitive data and ensure uninterrupted healthcare services. Strategic collaborations continue to drive innovation. SK Biopharmaceuticals' $795 million deal with Biohaven Pharmaceuticals aims to accelerate epilepsy therapy development targeting KV7 ion channels. Such partnerships exemplify how strategic investments can expedite drug development timelines and bring promising therapies to market faster. LabCorp's launch of a new hepatitis D test represents an advancement in diagnostic capabilities, aiming to identify patients with severe viral infections earlier, potentially leading to more timely interventions and better management of complications. Shifting our focus back to oncology, Revolution Medicines has achieved FDA approval for daraxonrasib, a RAS inhibitor targeting metastatic pancreatic cancer. With compelling data presented at ASCO, this approval signifies a breakthrough in treating RAS mutations—a challenging target implicated in many cancers. The drug's direct inhibition of mutated KRAS proteins disrupts cancer cell proliferation pathways considered "undruggable" until now. The implications are profound: daraxonrasib not only offers hope to patients with limited options but also sets new benchmarks for future RAS-targeted therapy development. It highlights precision medicine's growing trend—tailoring treatments based on genetic profiles to enhance effectiveness while minimizing side effects. In another significant advancement, Jazz Pharmaceuticals' Ziihera (zanidatamab) has been approved by the FDA as a first-line HER2-targeted therapy for gastroesophageal adenocarcinoma. This bispecific antibody represents a promising new class of treatment, enhancing options for patients with this aggressive cancer type and underscoring personalized medicine's importance in oncology. As we conclude today's update, these developments showcase how scientific breakthroughs, regulatory adaptations, and strategic collaborations collectively shape the future landscape of drug development and patient care globally. The industry remains dynamic as it navigates complexities while striving for innovative solutions that promise better health outcomes across diverse medical conditions. Stay tuned for more updates on Pharma Daily as we continue bringing you insights into the ever-evolving world of pharmaceuticals and biotechnology.Support the show

In this episode of the Transforming Primary Care podcast recorded in early summer 2026, a panel of pharmacists and pharmacy technicians chaired by Darren Archer, Senior Sustainability Manager for NHS England - North East and Yorkshire discuss the financial and environmental benefits of reducing medicines wastage. What do colleagues need to know about the success of local ‘Only Order What You Need' campaigns, and how do they help improve public health, save money and move the dial towards net carbon zero? For more information about Greener NHS visit: https://www.england.nhs.uk/greenernhs/ For more information about Greener NHS in the North East and Yorkshire region visit: https://www.england.nhs.uk/north-east-yorkshire/our-work/greener-nhs/ A full transcript of this episode is available on our website - https://www.england.nhs.uk/long-read/transforming-primary-care-podcast-series-5-episode-6-reducing-medicines-wastage-in-our-communities-podcast-transcript/ Please get in touch if you have any questions regarding this episode - england.ney.pctransformation@nhs.net

How can you use your voice to enact impact?  In the penultimate episode of our Leading the Way series, Dr Jonathan Darling, our recently departed Vice President for Education and Workforce, speaks with his successor, Dr Yincent Tse, a paediatric nephrologist. The two share valuable insights into leadership, quality improvement and the positive mindset needed to create lasting change.  Jonathan and Yincent discuss the importance of saying 'yes' to opportunities, but also knowing when it is time to move on. Yincent encourages leaders to talk to as many people as possible and to celebrate their colleagues. Coming from a quality improvement background, he approaches his work and leadership by bringing people together, starting small, using the psychology of change and measuring impact.  Yincent reflects on his experience growing up with a stammer and how this drove him to use his voice to make connections and centre the voices of his colleagues and patients. An example of this is KidzMed, which started as a conversation between Yincent and his colleagues and patients about the challenges of liquid medicine for children. The result was a QI project across hospitals which converted many CYP from liquid to tablet medicine.  Yincent leads with a positive attitude that drives solution-oriented change. Two taekaways for listeners: use your voice and apply quality improvement principles. Read Jonathan's reflections and download the transcript from episode 14 on RCPCH website: https://www.rcpch.ac.uk/news-events/news/2026-08/leading-way-episode-14-leading-through-improvement-dr-yincent-tse KidMed resource for helping your child to swallow tablets on Medicines for Children: https://www.medicinesforchildren.org.uk/news/helping-your-child-to-swallow-tablets-new-resources-from-kidzmed/ Grand round webinar series on RCPCH website: https://learning.rcpch.ac.uk/home/webinars/rcpch-grand-round-webinar-series-2025-26/ Trainee Research Network on RCPCH website: https://www.rcpch.ac.uk/resources/rcpch-trainee-research-network Discover more of our podcasts on RCPCH Learning: https://learning.rcpch.ac.uk/home/podcasts/ The views, thoughts and opinions expressed in this podcast relates only to the speaker and not necessarily to their employer, organisation, RCPCH or any other group or individual. About Yincent Dr Yincent Tse is a paediatric nephrologist in Newcastle. He served as our Area Officer for North England, later co-chaired our joint Medicines Committee and lead on our Grand Rounds webinar series. In May 2025, Yincent started his post as Vice President for Education and Workforce.

Last week, startling headlines hit the news. Three commonly prescribed medicines, hydrochlorothiazide, used to treat high blood pressure, voriconazole, an antifungal medicine and tacrolimus, an immunosuppressant were classified as carcinogenic, or cancer causing, to humans. The classification was made by the International Agency for Research on Cancer or IARC, which is the World Health Organization's cancer research agency.According to the IARC, there is sufficient evidence that hydrochlorothiazide causes squamous cell carcinoma of the skin and cancer of the lip, as the drug makes the skin more sensitive to ultraviolet radiation. Voriconazole, also has been linked to the same cancers. In the case of Tacrolimus since it suppresses the immune system to prevent rejection of transplanted organs, the reduced immune surveillance may allow abnormal cells to proliferate and it is linked with non-Hodgkin lymphoma with limited evidence for other cancers as well.These drugs are prescribed to millions of people worldwide. So what happens now? Guest: Dr. Rajeev Jayadevan convener, research cell, Kerala State IMA and honorary senior consultant gastroenterologist, Sunrise Hospital, Kochi. Host: Zubeda Hamid Edited by Sharmada Venkatasubramanian Learn more about your ad choices. Visit megaphone.fm/adchoices

We could really use some healing after last episode's nightmare, so along comes the medic fantasy manga The Beast King: Master of Medicines! And good news, it's better than the last series we did about a healer. But will this story of demon and human working together to cure monsters and save the world be the tonic we so desperately need? ~ Welcome to That Time I Started A Podcast To Read Trash Manga With My Friends And Actually Most Of Them Were Trash But Some Of Them Weren't! Or The Trash Manga Friends Podcast, for short. The trash journey never ends! Every fortnight our trio of hosts, Sean, Mike and Phil, pick out a manga, webtoon, manhua or manhwa, read the first two volumes (or equivalent), and then spend the next hour or so having an existential breakdown about it. Some are good! Some are bad. Most are trash. So join us, for our seventh year, as we slowly close in on 200 episodes and series covered! ~ Follow us on social media! Links to all platforms on our site - https://trashmangafriends.carrd.co/ Sean, your, say it with us, foooreeeeveeeer host, can be found on Bluesky & Twitch - https://bsky.app/profile/slazo.bsky.social ~ https://www.twitch.tv/slazoking Mike, your streamer haternaire, can be found everywhere @Bersekrer - https://bersekrer.carrd.co/ Phil, your master of trashimonies, can't be found on Twitter @PheNaxKian - https://twitter.com/PheNaxKian ~ Support the official release! The Beast King: Master of Medicines is licensed by Seven Seas Entertainment - https://sevenseasentertainment.com/series/the-beast-king-master-of-medicines/

Jason Coloma, CEO of South San Francisco-based Maze Therapeutics, on developing small molecule drugs based on human genetics for kidney diseases.

Cada vez mais pessoas têm contato com o uso de Ayahuasca e dos famosos "cogumelos mágicos". Mas pouco se sabe sobre os impactos que essas substâncias têm na nossa saúde. O que a ciência sabe, hoje, sobre isso? Confira o papo entre o leigo curioso, Ken Fujioka, e o cientista PhD, Altay de Souza. >> OUÇA (57min 07s) * SOBRE O NARUHODO Naruhodo! (@naruhodopodcast) é o podcast pra quem tem fome de aprender. Ciência, senso comum, curiosidades, desafios e muito mais. Com o leigo curioso, Ken Fujioka (@kenfujioka), e o cientista PhD, Altay de Souza (@altayals). Edição: Reginaldo Cursino (@reginaldocursino) Ilustração e Capa: Felipe Cruz (@felipecruzart) http://naruhodo.b9.com.br * REFERÊNCIAS Psychedelics as Medicines for Substance Abuse Rehabilitation: Evaluating Treatments with LSD, Peyote, Ibogaine and Ayahuasca https://www.ingentaconnect.com/content/ben/cdar/2014/00000007/00000002/art00005 A Systematic Review on the Therapeutic Effects of Ayahuasca https://www.mdpi.com/2223-7747/12/13/2573 Ayahuasca Treatment Outcome Project (ATOP): One-Year Results from Takiwasi Center and Implications for Psychedelic Science https://www.jsad.com/doi/abs/10.15288/jsad.23-00005 Ayahuasca-assisted meaning reconstruction therapy for grief: a non-randomized clinical trial protocol https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2024.1484736/full The Future of the Biopsychosocial Model: Toward a Transdisciplinary Systems Science of Mental Health  https://media.eiko-fried.com/publications/2026-robinaugh-clinical-psychological-science-the-future-of-the-biopsychosocial-model.pdf Lopes, Inês Magalhães (2017). Do Kamo, Ser-no-mundo e a Universalização da Concepção Individualista de Pessoa (PDF). Lisboa: Instituto Universitário de Lisboa, Escola de Ciências Sociais e Humanas The Legacy of Maurice Leenhardt https://journals.sagepub.com/doi/10.1177/239693938901300408 Ayahuasca and the traveller: A scoping review of risks and possible benefits https://www.sciencedirect.com/science/article/abs/pii/S1477893921002477 Mental Disorders as Homeostatic Property Clusters A Narrative Review  https://media.eiko-fried.com/publications/2026-fried-jama-psychiatry-mental-disorders-as-homeostatic-property-clusters-a-narrative-review.pdf Revisiting the theoretical and methodological foundations of depression measurement  https://media.eiko-fried.com/publications/2022-fried-nature-reviews-psychology-revisiting-the-theoretical-and-methodological-foundations-of-depression-mea.pdf Reassessing the cultural and psychopharmacological significance of Banisteriopsis caapi: preparation, classification and use among the Piaroa of Southern Venezuela https://pubmed.ncbi.nlm.nih.gov/19004422/ Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial https://pmc.ncbi.nlm.nih.gov/articles/PMC6378413/ The Psychedelic Future of Post-Traumatic Stress Disorder Treatment https://www.benthamdirect.com/content/journals/cn/10.2174/1570159X22666231027111147 Risk of bias in randomized clinical trials on psychedelic medicine: A systematic review https://journals.sagepub.com/doi/full/10.1177/02698811231180276 How to set up a psychedelic study: Unique considerations for research involving human participants https://www.sciencedirect.com/science/article/pii/S0149763426001144 Psycholytic Therapy Using LSD: a Realist Review https://onlinelibrary.wiley.com/doi/full/10.1002/brb3.71187 Safety and Efficacy of Repeated Low-Dose LSD for ADHD Treatment in Adults https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2831639 Preliminary Findings on Low-Dose 1cp-LSD for Canine Anxiety: Exploring the Role of Owner Neuroticism and Psychopathology https://www.mdpi.com/2306-7381/12/9/872 Efficacy and Safety of LSD in the treatment of mental and substance use disorders: A systematic review of randomized controlled trials https://www.sciencedirect.com/science/article/abs/pii/S0165178125002707 Evaluating the Impact of a Low Dose of LSD on EEG Spectral Signature in Participants with Depressed Mood (Abstract ID: 163720) https://jpet.aspetjournals.org/article/S0022-3565(24)42708-0/fulltext Efficacy and safety of low- versus high-dose-LSD-assisted therapy in patients with major depression: A randomized trial https://www.cell.com/med/fulltext/S2666-6340(25)00152-7 Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial  https://repositorio.ufrn.br/server/api/core/bitstreams/79cb4dd8-9bca-4b4a-832b-b6940029b65b/content Naruhodo #266 - Por que vemos luzes quando fechamos os olhos?  https://www.youtube.com/watch?v=3_4r_ZGb4wA Naruhodo #220 - Existe causa para a depressão? - Parte 1 de 2  https://www.youtube.com/watch?v=cFo8GFwyuR0 Naruhodo #221 - Existe causa para a depressão? - Parte 2 de 2  https://www.youtube.com/watch?v=5peXBmG43lU Naruhodo #419 - Maconha faz mal? - Parte 1 de 2  https://www.youtube.com/watch?v=cvLTh2bKPiQ Naruhodo #420 - Maconha faz mal? - Parte 2 de 2  https://www.youtube.com/watch?v=F7wVcGvpoGA Naruhodo #106 - Hipnose funciona? - Parte 1 de 2  https://www.youtube.com/watch?v=XIHUilfmAzQ Naruhodo #107 - Hipnose funciona? - Parte 2 de 2  https://www.youtube.com/watch?v=O42Yo2zt5vs Naruhodo #461 - O que é a teoria da Incompletude de Godel?  https://www.youtube.com/watch?v=XQRu2ogFvMQ * APOIE O NARUHODO! O Altay e eu temos duas mensagens pra você. A primeira é: muito, muito obrigado pela sua audiência. Sem ela, o Naruhodo sequer teria sentido de existir. Você nos ajuda demais não só quando ouve, mas também quando espalha episódios para familiares, amigos - e, por que não?, inimigos. A segunda mensagem é: existe uma outra forma de apoiar o Naruhodo, a ciência e o pensamento científico - apoiando financeiramente o nosso projeto de podcast semanal independente, que só descansa no recesso do fim de ano. Manter o Naruhodo tem custos e despesas: servidores, domínio, pesquisa, produção, edição, atendimento, tempo... Enfim, muitas coisas para cobrir - e, algumas delas, em dólar. A gente sabe que nem todo mundo pode apoiar financeiramente. E tá tudo bem. Tente mandar um episódio para alguém que você conhece e acha que vai gostar. A gente sabe que alguns podem, mas não mensalmente. E tá tudo bem também. Você pode apoiar quando puder e cancelar quando quiser.  O apoio mínimo é de 15 reais e pode ser feito pela plataforma ORELO ou pela plataforma APOIA-SE. Para quem está fora do Brasil, temos até a plataforma PATREON. É isso, gente. Estamos enfrentando um momento importante e você pode ajudar a combater o negacionismo e manter a chama da ciência acesa. Então, fica aqui o nosso convite: apóie o Naruhodo como puder. bit.ly/naruhodo-no-orelo

DR PAM KRYSKOW is the medical lead for the Roots To Thrive Program. She is actively involved in research related to psilocybin, MDMA, ketamine and front line health care workers and first responders’ mental wellness. She is co-investigator on the largest microdosing study Microdose.me. Home

https://rumble.com/user/TheCultureWarshttps://x.com/NewsK365https://buymeacoffee.com/courtpresshttps://www.youtube.com/@NewsK365Email: newsk365@protonmail.com

Every Wednesday afternoon, we'll be talking Making Babies.Andrea will be joined by Professor Shane Higgins, Consultant Obstetrician and Gynaecologist, to cover every area of trying to have a baby. From the very start of knowing how to prepare, right up to pregnancy – and all the bumps in the road in between.This week, Shane joins Andrea to discuss everything you need to know about taking medicines during pregnancy.

Host Ben Plumley speaks with Solange Baptiste Simon and Othoman Mellouk of the International Treatment Preparedness Coalition (ITPC) about their packed treatment pre-conference and concerns that treatment is being sidelined amid heavy focus on PrEP and prevention. They argue the prevention-versus-treatment framing is false, emphasizing a continuum from testing to prevention to treatment, and describe on-the-ground chaos as HIV services are integrated into broader chronic care with overstretched health workers and communities. They discuss a “strange” AIDS 2026 marked by funding cuts and reduced PEPFAR influence, uneven country leadership, and a shift from scientific innovation to challenges of financing, manufacturing, regulation, and equitable delivery of long-acting technologies. They caution against product-driven responses, stress human rights and stigma realities, and conclude that community power, involvement, and resourcing remain central to sustainable solutions. 00:00 Welcome and Guests 01:08 Treatment Preconference Highlights 03:13 Prevention vs Treatment Debate 05:00 Continuum of Care Reality 07:34 Clinic Integration Chaos 10:07 Conference Avoiding Hard Truths 14:58 Post PEPFAR Future 18:39 Product Hype vs Access 22:58 Fiscal Space and Priorities 25:13 Beyond Biomedical Fixes 30:19 2030 Targets Reality Check 32:29 Crossroads and Policy Choices 36:15 Community Hope and Closing 38:23 Final Thanks and Signoff Guests: Solange Baptiste Simon Executive Director, ITPC Othoman Mellouk Access to Medicines & Diagnostic Lead, ITPC ITPC Global https://itpcglobal.org AIDS 2026 https://www.iasociety.org/conferences/aids2026 Check Out Ben's Substack: https://substack.com/@benplumley1 Join the Conversation! How do you see the future of global health unfolding? Share your thoughts in the comments! Subscribe & Stay Updated: Listen on Spotify, Apple Podcasts, or your favorite podcast platform. Watch on YouTube & subscribe for more in-depth global health. #hivaids #HIV #AIDS #globalhealth #AIDS2026 #ITPC

Ever been curious about psychedelics? If so, you're not alone. But consuming psychedelic plant medicines has always been taboo, even when it comes to healing modalities. Over the years, more research has shown that plant medicines, when taken with intention, can have a positive impact on one's psyche and healing journey. Katherine Petrullo is the founder of Lüminate and creator of Women of Impact. Her work weaves together Taoist philosophy, tantra, kundalini, and plant medicine. Before her success, she was a young woman quietly falling apart, cycling through rock bottoms, and reaching for anything external that might make her feel whole, a feeling she had never truly known. Katherine explains what finally shifted, including a plant medicine ceremony, and what she learned on the other side of it. Click 'play' to see if psychedelics might be your next (unexpected) healing modality.What You Will Learn[00:07:30] Childhood existential anxiety — and distorting her voice to feel safe[00:13:30] Why plant medicine wasn't the magic bullet she expected[00:17:00] Why not feeling safe to share kept her deeply isolated[00:30:30] What her first ayahuasca ceremony actually felt like — and the dark night of the soul that followed[00:36:00] What coming back into the body actually felt like[00:46:00] How the medicine wheel explains why so many people experience energy crashes and empty creation[00:53:30] What Women of Impact is — and what it's actually designed to do[01:01:00] Why healing isn't something you're always doing — it's a danceResources MentionedMany Lives, Many Masters by Brian WeissLet's Connect!Katherine PetrulloWebsite | InstagramChandler StroudWebsite | LinkedIn | InstagramHappiness Academy is now Healing Heroines, a signature space for women who are ready to feel more grounded, more peaceful, and more aligned — inside and out. Download a complimentary Healing Roadmap to discover our Past, Present, and Possible framework.Want personalized guidance for your healing journey? Book a call with Chandler!Mixing and editing provided by Next Day Podcast.Text message us questions, requests, or comments!

Lyn Baranowski, CEO of Boston-based Avalyn Pharma, on developing inhalable medicines for severe lung diseases.

China's high-tech sectors are gaining global traction, with surgical robot exports jumping 330% in the first half as AI, robotics and innovative medicines emerge as new pillars of growth.

Dr. Cristine Hull is an integrative mental health practitioner, author, and developer of the Zero Point Meridian technique. With a Master's in Psychology and a Ph.D. in Natural Medicine, she brings over two decades of experience as a substance abuse counselor, school psychologist, and private practitioner. Drawing from her own journey through depression, anxiety, addiction, and a profound spiritual awakening, Cristine works at the intersection of brain chemistry, energy medicine, and the quantum field. She is the creator of the Four Bodies model and trains practitioners in tools that address the physical, vital, mental, and quantum levels of healing. Based in northern Utah, she continues to teach, write, and guide people toward deeper wholeness through her work at Health, Healing & Wholeness.In this episode, Cristine and I cover a wide-ranging conversation that moves from brain chemistry and addiction into spiritual awakening, energy medicine, and what real healing actually requires.Cristine shares her personal journey through severe depression, anxiety, and substance use, and how those experiences led her into decades of work as a counselor and integrative practitioner. She introduces her Four Bodies model (physical, vital, mental, and quantum) and explains why most lasting change has to address more than just the physical level. The conversation explores sugar as part of the narcotic continuum, the difference between dopamine and endorphin addiction, the spiral of recovery she developed while teaching in a jail, and the powerful spiritual experience she had on Yom Kippur that shifted everything. We also dig into entities and generational energy, the development of her Zero Point Meridian technique, the “neutral game” for quieting the mental body, and why conventional mental health often falls short with personality disorders and chronic pain. Cristine closes by pointing back to the deeper truth underneath the endorphin chase: capital-L Love.Timestamps0:00 – Elevator pitch / “junkyard love” framing and four bodies intro1:30 – Four Bodies for Medicines ebook and physical vs. vital/mental/quantum3:00 – Wind analogy for spirit/effects on the physical body4:30 – Personal history: chemical imbalance, depression, anxiety, substances6:30 – First career in substance-abuse counseling; self-medication insight8:00 – Serotonin, carbs, Potatoes Not Prozac, wheat sensitivity discovery9:30 – Endorphins as “inner orphan” / morphine parallel; sugar as narcotic continuum11:00 – Dopamine vs. endorphins; cocaine, bipolar diagnosis, mastering the middle path13:00 – Love addiction, romantic craving, spiral model (abstinence → moderation → attainment)15:00 – Jail curriculum development; 20 years clean vs. relationship patterns still unresolved16:30 – Yom Kippur night/boyfriend breakup; Day of Atonement context18:00 – Light shaft experience through the crown/spine; “whole and complete through divine connection”19:30 – Kundalini as vital-body tool (chakras, meridians, aura)21:00 – Growing up Christian, leaving religion, seeking freedom from guilt and pain22:30 – Cocaine phase; friend returning from overdose funeral; entity/attachment theory24:30 – “Perverse energy” (Quantum University language); generational clearing26:00 – First Kundalini session clearing grandfather's heavy emotion27:30 – EFT training (2002–2003, Gary Craig); shift to private practice29:00 – Zero Point Meridian (ZPM) development; claimed superiority data vs. EMDR31:00 – Mental body chaos of positive/negative thinking; neutrality / “neutral game”34:00 – Yoga entry via client accountability + Baron Baptiste Journey into Power36:00 – Gap between stimulus and response; mind-body necessity of yoga37:30 – TM interest; Vipassana documentary (Doing Time, Doing Vipassana)39:00 – Mahasati movement meditation; fear that stillness = non-existence / black hole41:00 – Moving through zero; zero-point field → unified field; John Hagelin / Frank Kinslow52:00 – Limits of conventional mental health on personality disorders (narcissism, borderline, ego structures)54:00 – Spiritual/quantum solution as transformative where pills and talk therapy fall short56:00 – Quantum Solutions Masterclass / ego-structure component57:30 – Chronic pain and the pain body (Eckhart Tolle); noticing pain-free body parts as anchors59:00 – Endorphins at quantum level = capital-L Love; closing gratitudeKEYWORDS:Four bodies model, Zero Point Meridian, ZPM technique, quantum body, vital body, endorphin continuum, sugar addiction recovery, love addiction spiral, attainment model, perverse energy, generational clearing, Yom Kippur awakening, Kundalini vital body, neutral game mindfulness, Quantum Wholeness Meditation, Love Solve Method, Frequency Formulas, personality disorder spiritual solution, pain body Eckhart Tolle, brain chemistry natural balance, EFT to ZPM evolution, Cache Valley healer, integrative mental health Utah.Checkout more Cristine here! :Website: Cristine HullYoutube - Health, Healing, & Wholeness - YouTubeInstagram - Author Cristine Hull (@cristine.author)LinkedIn - Cristine Hull PhD LinkedinFaceBook - Author Cristine Hull • FacebookQuotes from Cristine in the episode:“Love is an answer. It's a solution for sure.”“The wind is actually the spirit. The effects are the physical body.”“Endorphins… stands for inner orphan, which like morphine… highly addictive… sugar.”“The trick was not to try to change it and stay up. The trick was to realize when I was down, there was some work to do…”“Really, all that matters is that you are whole and complete through a divine connection. And you bring your whole self to it.”“I believe the person who overdosed came with her and walked through the door… this entity… attached to me.”“If we try to use the mind to correct the mind, we can get just a lot of chaos… the solution… is neutrality.”“There's not a lot in mental health and psychology to solve personality disorders… the problem is because there's not really a spiritual solution in the mental health field.”“Notice where you're not in pain - tune into even if it's your hair… their hair doesn't hurt, the tip of their nose probably doesn't hurt…”“What people are looking for in the endorphin experience is love. And it's a capital L-O-V-E…”If you enjoyed our conversation - please like, subscribe, and we'll see ya next on the next episode!

Patients wating for life-changing medicines to be funded say people should not have to fundraise, got into debt or travel overseas for treatments and therapies that could be administered here. The Forbidden Pharmacy at Auckland's Shed 10 is an installation showing shelves of medicines locked behind doors, representing what people may need but can't access because they are not funded by Pharmac. Amy Williams reports.

Mental health remains one of medicine's greatest unmet needs. In this episode, Jacob Hooker explains how Sensorium Therapeutics is searching for new psychiatric medicines by combining traditional plant knowledge with cutting-edge drug development. Jacob joins Rafael Rosengarten to discuss how centuries of ethnobotanical knowledge, modern AI, and medicinal chemistry are helping uncover new treatments for anxiety, epilepsy, and cognitive disorders. Along the way, they explore the science behind psychoactive plants, the growing global burden of mental health conditions, and what the future of psychiatric medicine could look like if researchers can move beyond symptom management toward lasting brain health.TPM E59 highlights >⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Episode 59 links:Sensorium Therapeutics Aether in Mind SubstackBook recommendationsRichard Evans Schultes: Plants of the GodsMark J. Plotkin: Tales of a Shaman's Apprentice Wade Davis: One River The Plants of the Gods podcastUpdated trends in the global prevalence and burden of mental disorders, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023Americans for Ibogaine

The rise of weight loss jabs could completely change the way people shop, and not just for food, according to a leading business consultancy. A new report by EY looks at the way GLP1 weight loss medicines are influencing consumer choices in Australia and what that could mean for business. Report co-author, Lisa Nijssen-Smith spoke to Lisa Owen.

India is often called the ‘pharmacy of the world' — it exports one-fifth of the world's generic medicines and meets over half of the global vaccines demand. Yet when it comes to discovering the next breakthrough medicine, India's contribution remains surprisingly small.----more----Read full article here: https://theprint.in/feature/india-manufacturing-medicines-discovering-funding-key/2973560/

Americans pay roughly three times as much for prescription meds as people in other wealthy nations. But why? Tahir Amin argues it's largely to do with how our patent systems work. He's been on both sides of the issue: He spent a decade as an intellectual property lawyer, helping corporations use patents to protect their bottom lines. Then he moved to India and saw firsthand how the global patent system hampered access to HIV drugs. That led him to shift gears and create an advocacy organization aimed at changing the patent system to make access to medicines more equitable. He chats with Flora about how it all works, and his new book, “Pharma Monopoly.” Read an excerpt from “Pharma Monopoly: The Battle for the Future of Medicines.” Guest: Tahir Amin is a co-author of “Pharma Monopoly: The Battle for the Future of Medicines” and a founder and CEO of Initiatives for Medicine Access and Knowledge (I-MAK).  Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Follow our show on Instagram, TikTok, Facebook, and Bluesky @scifri and sign up for our newsletters. Got a science question that's keeping you up at night? Call us: 877-472-4374 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

For the last episode in the second series of Magic and Medicines, we're talking about Palmistry and Phrenology!We start by looking at uses of palmistry across the world, from Vedic astrology with Hindu Jyotish over to the divination practices of the Chinese Ming dynasty.We discuss whether or not it's true that Aristotle discovered an ancient palmistry text and got Alexander the Great into the art, and explore the stereotypes associated with fortune telling in general, and some nasty xenophobic history.Then, we have a look at our own hands, and try and work out whether we've got 'fire hands' or 'air hands', and what the lines in our palms say about us.In the third part of the episode, we look at the concept of phrenology, from its roots as possible brain science through to its manipulation and abuse by proponents of eugenics, and its alarming similarity to the work done by some algorithms today...We really hope you enjoy the episode, and we will speak to you again on Thursday with a new tale from the Red Fairy Book, Minnikin!Three Ravens is an English Myth and Folklore podcast hosted by award-winning writers Martin Vaux and Eleanor Conlon.Released on Mondays, each weekly episode focuses on one of England's 39 historic counties, exploring the history, folklore and traditions of the area, from ghosts and mermaids to mythical monsters, half-forgotten heroes, bloody legends, and much, much more. Then, and most importantly, the pair take turns to tell a new version of an ancient story from that county - all before discussing what that tale might mean, where it might have come from, and the truths it reveals about England's hidden past...Bonus Episodes are released on Thursdays plus Local Legends episodes on Saturdays - interviews with acclaimed authors, folklorists, podcasters and historians with unique perspectives on that week's county.With a range of exclusive content on Patreon, too, including audio ghost tours, the Three Ravens Newsletter, and monthly Three Ravens Film Club episodes about folk horror films from across the decades, why not join us around the campfire and listen in?REGISTER FOR THE TALES OF SOUTHERN ENGLAND TOURVisit our website Join our Patreon Social media channels and sponsors Hosted on Acast. See acast.com/privacy for more information.

Scientists have made a new scientific breakthrough in the study of the human body.Researchers in the United States have discovered something amazing: a third circulatory system within the human body.Alongside the previously known cardiovascular and lymphatic systems, this interstitium system (as it's being called) appears to allow the different organs of the human body to pass things along to one another.Which in-and-of-itself is an amazing discovery, but it's made even more exciting by the fact that this newly discovered system maps very well onto the model of the human body that's been used in traditional Eastern medicine for thousands of years (in practices like acupuncture, for instance).Meaning, this discovery might very well be the missing link between Western and Eastern medicine.Let's go through the details together.